Organ On A Chip Market Size, Share & Trends Analysis Report By Product & Service (Products, Services), By Application (Drug Discovery, Toxicology Research), By End-use, By Region, And Segment Forecasts, 2024 - 2030

Organ On A Chip Market Size & Trends

The global organ on a chip market size was estimated at USD 117.1 million in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 35.01% from 2024 to 2030. The growth of the market can be attributed to the increasing prevalence of chronic diseases which necessitates faster drug discovery techniques, increasing demand for drug toxicity detection, technological advancement, and rising product launches by key market players. The COVID-19 pandemic had a positive impact on the market. To understand the pathophysiology of the liver in COVID-19 patients, researchers employed organ-on-a-chip technology to create liver models simulating the regions around blood vessels or bile ducts.

According to the Center for iPS Cell Research and Application, Kyoto University article, published in March 2023, researchers used microfluidic devices to culture human hepatocytes and cholangiocytes in separate channels, forming liver-on-a-chip models with intrahepatic bile ducts (ibd-LoC) and blood vessels (bv-LoC). After two days, infection with SARS-CoV-2 revealed viral presence in both bv-LoCs and ibd-LoCs.

In October 2023, the BARDA, under the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), collaborated with the Wyss Institute at Harvard University. This collaboration is expected to enhance Wyss Institute's human Organ Chip platform and drug discovery capabilities. The focus is primarily on gaining a deeper understanding of illnesses and injuries resulting from various health threats, such as high doses of radiation. Another goal of this collaboration is to predict and assess potential treatments for these health challenges.

Moreover, according to the American Cancer Society, in 2023, about 238,000 new cases of lung cancer will be detected in the U.S. Hence, companies are investing in developing organ-on-a-chip platforms. In June 2022, the Charles Stark Draper Laboratory, Inc. launched its lung-on-chip model where-in the scientists employed various infection metrics, and examined around 3,000 data points, to identify antiviral compounds that successfully inhibited viral replication in the lung tissue models.

Product & Service Insights

Based on product & service, the services segment dominated the market with a revenue share of 52.49% in 2023. This can be attributed to the increasing demand for specialized services in designing, developing, and customizing organ-on-a-chip platforms. Research institutions, pharmaceutical companies, and biotechnology firms seek expertise from service providers to leverage advanced organ-on-chip technologies for drug discovery, toxicity testing, and disease modeling. Service providers offer a range of solutions, including designing custom organ-on-chip models, conducting experiments, and providing analysis services. This trend reflects the industry's recognition of the value of outsourcing specific aspects of organ-on-chip research to dedicated service providers, leading to the prominence of the service segment in the market.

However, the products segment is anticipated to grow at the fastest CAGR of 36.20% from 2024 to 2030. The high growth rate of the segment is attributed to the increasing R&D, product launches, and rising prevalence of chronic diseases. Furthermore, the growth of cell and molecule-based immunotherapies is driving the market growth. In August 2023, a group of bioengineers and immune-oncologists conducting research at the Wyss Institute for Harvard Medical School (HMS), Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS), Biologically Inspired Engineering at Harvard University, and the Roche Innovation Center in Germany and Switzerland, designed an organ-on-chip model featuring immune-infiltrated human kidney organoids. These organoids consist of miniature kidney tissue segments with vasculature and developing nephrons that allow contact with circulating immune cells.

Application Insights

The application segment consists of drug discovery, toxicology research, and others segments. The drug discovery segment dominated the market in 2023 with a revenue share of 62.87%. There is a critical need for in vitro tissue models that mimic the functioning of specific human organs in vitro while developing new drugs. The challenges in novel drug discovery, marked by escalating costs and a low likelihood of success in clinical trials, stem from the need for more predictive preclinical in vitro models. Hence, companies are investing in developing and advancing organ-on-a-chip technology. For instance, in March 2022, The Charles Stark Draper Laboratory, Inc., a supplier of organ-on-a-chip and bioprocessing systems, announced a strategic plan for its organ-on-a-chip technology to align with the increasing emphasis on targeted and advanced therapeutics in drug development. The company plans to introduce new human organ models, sophisticated data acquisition, and analysis tools for applications across various drug discovery and development stages. It includes assessing drug toxicity, gauging efficacy in disease states, and testing therapeutic interventions.

The toxicology research segment is anticipated to register the fastest CAGR of 37.50% from 2024 to 2030. Invasive fungal infections pose a significant global health threat, with a mortality rate exceeding 1.6 million deaths annually, despite available anti-fungal treatments. The current therapies lack precise targeting, leading to considerable systemic toxicity. To address this challenge, in September 2023, the Wyss Institute team introduced the Fungicidal endovascular Controlled-release Iron-binding Lectin Liposomes (FeCILL), designed to target the fungal cell wall and concentrate drugs in that location. Organ-on-a-chip platforms can prove to be beneficial for studying such therapies and toxicity testing.

End-use Insights

The pharmaceutical & biotechnology companies segment captured the largest market share of 73.03% in 2023. This can be attributed to substantial investments in R&D, a focus on personalized medicine, product launches, and the need for advanced drug testing technologies. For instance, in March 2023, Nippon Telegraph and Telephone Corporation (NTT), based in Tokyo, achieved the development of an on-chip actuator capable of replicating organ movements. This breakthrough leverages NTT's distinctive shape-morphing technique, on-chip, to transform a hydrogel film responsive to light stimulation into a thin-film tube resembling organ structures.

The academic and research institutes segment is anticipated to register the fastest CAGR of 39.27% from 2024 to 2030. The rapid growth of the academic and research institutes segment in the organ-on-a-chip industry is attributed to its role as a hub of innovation and research. In March 2022, a research team from the University of Toronto's Faculty of Applied Science & Engineering, utilizing the organ-on-a-chip platform identified a potential catalyst for the organ-on-a-chip industry—the QHREDGS molecule. This innovative anti-inflammatory peptide doesn't directly target the virus but addresses a critical complication of COVID-19 infections by averting cytokine storms. The molecule's capability to mitigate cytokine storms emerges as a promising driver in combating severe outcomes of COVID-19 and related illnesses, highlighting the key role of organ-on-a-chip technology in drug discovery and understanding intricate physiological responses.

Regional Insights

North America dominated the organ-on-a-chip industry with the largest revenue share of 50.23% in 2023, and the region is projected to register the fastest growth over the forecast period. The growth is attributed to the presence of key market players in the region and government initiatives. Moreover, the rising prevalence of chronic disease is driving the regional market. For instance, in 2021, as a response to the COVID-19 pandemic, the FDA collaborated with the National Institute of Allergy and Infectious Diseases (NIAID) to progress the development of organs-on-chips and microphysiological systems (MPS) models. The collaboration aimed to facilitate the creation and assessment of Medical Countermeasures (MCMs) for COVID-19. The Wyss Institute, in partnership with the UK Health Security Agency (formerly Public Health England), utilized its organs-on-chips technology to enhance the in vitro (human) models for studying viral infection, propagation, and pathogenicity. In 2023, the FDA granted a partial option award to further propel the development and characterization of organ chips dedicated to radiation countermeasure research. This option involves evaluating the efficacy of radiation countermeasures using organ chips and screening additional experimental compounds for Medical Countermeasures (MCM).

The Europe region is expected to exhibit substantial growth with a CAGR of 34.50% over the forecast period. The regional growth is mainly driven by the rising prevalence of chronic conditions, technological advancements, government initiatives, and rising R&D initiatives by non-profit organizations. In September 2023, according to the European Organ-On-Chip Society, scientists from Tampere University's Centre of Excellence in Body-on-Chip Research (Finland) released a review that describes the construction of microphysiological systems for simulating cardiac functions. The review delves into the center's emphasis on modeling brain stroke, hypoxia in cardiac ischemia, and obesity-related conditions. The core activities include developing monitoring technologies for oxygen control, creating chip platforms, and advancing hydrogel development.

Key Companies & Market Share Insights

The key players in the market are undertaking various strategic initiatives to maintain their dominance. For instance, in September 2023, a collaborative research effort between Hesperos, Inc. and the University of Central Florida successfully created the initial human-on-a-chip to investigate the impacts of an opioid overdose and the subsequent reversal using naloxone. Moreover, in June 2023, Emulate, Inc. announced the launch of the A1 Accessible Chip, an Emulate Chip, through an early access program. Building upon the foundation of the original Chip-S1, which replicates tissue-vascular interfaces with biomechanical forces like stretch and flow, the new Organ-Chip design enables users to generate thicker tissues within the epithelial culture chamber. In addition, it provides the flexibility to implement various drug treatment options, including aerosolized or topical applications.

Organ On A Chip Market Report Scope

Global Organ On A Chip Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global organ on a chip market report based on product & service, application, end-use, and region.

• Product & Service Outlook (Revenue, USD Million, 2018 - 2030)

  • Products

  • Instruments

  • Organ-on-a-Chip Devices

  • Liver-on-a-Chip

  • Lung-on-a-Chip

  • Intestine-on-a-Chip

  • Kidney-on-a-Chip

  • Heart-on-a-Chip

  • Others

  • Services

• Application Outlook (Revenue, USD Million; 2018 - 2030)

  • Drug Discovery

  • Toxicology Research

  • Others

• End-use Outlook (Revenue, USD Million; 2018 - 2030)

  • Academic and Research Institutes

  • Pharmaceutical & Biotechnology Companies

  • Others

• RegionalOutlook (Revenue, USD Million, 2018- 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait